Condition

HER2-positive Breast Cancer clinical trials and research

• 83Clinical trials
• 11NIH research projects
• 1New in 30 days
• 38Countries

Newest HER2-positive Breast Cancer clinical trials

All recruiting trials (83)

• Can we skip radiation after lumpectomy for low-risk HER2-positive breast cancer?

  This study tests whether patients who had breast-conserving surgery and low-risk HER2-positive breast cancer can safely skip radiation therapy while receiving HER2-targeted treatment.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07895511

• Breast cancer subtypes and outcomes in Colombian women

  This study looks back at medical records of women with breast cancer to see how different molecular subtypes relate to survival and recurrence in a single Colombian hospital.

  Recruiting Fundación Santa Fe de Bogota · Bogotá, Bogota D.C. · NCT07856225

• SMP-656 in HER2-positive advanced breast cancer after ADC therapy

  This trial tests whether SMP-656 given by IV every 3 weeks can help people with HER2-positive locally advanced or metastatic breast cancer who progressed after a HER2-targeted antibody-drug conjugate.

  Recruiting Phase 2 Chengdu SciMount Pharmatech Co., Ltd. · Hefei, Anhui and 14 other locations · NCT07726342

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

• GQ1005 versus T-DM1 in HER2-positive unresectable or metastatic breast cancer

  This trial tests whether GQ1005 works as well as T-DM1 for adults with HER2-positive unresectable or metastatic breast cancer who have already had trastuzumab and taxane.

  Recruiting at 70 sites Phase 3 GeneQuantum Healthcare (Suzhou) Co., Ltd. · Bengbu, Anhui and 69 other locations · NCT07673029

• Trastuzumab Rezetecan Neoadjuvant Therapy for HER2-Positive Breast Cancer

  This trial tests whether adding trastuzumab rezetecan after an initial THP treatment helps patients with HER2-positive breast cancer decide if they should switch therapies based on response.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07647263

• Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer

  This study tests a treatment combination of Pyrotinib, Trastuzumab and chemo given before surgery to see if it can improve responses in HER2-positive breast cancer patients who have not yet been treated.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT07635342

• Focused ultrasound-guided targeted drug delivery with neoadjuvant therapy for HER2-positive breast cancer

  This study tests a focused ultrasound–driven drug delivery approach added to neoadjuvant therapy for women with HER2-positive breast cancer to see if it’s feasible, safe, and shows early signs of effectiveness.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07616440

• BL-M07D1 plus pertuzumab vs standard therapy in first-line HER2-positive breast cancer

  A Phase 3 trial tests whether adding BL-M07D1 to pertuzumab is as good as or better than docetaxel plus trastuzumab and pertuzumab in patients with newly diagnosed, unresectable or metastatic HER2-positive breast cancer.

  Recruiting at 2 sites Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07518173

• Dual-target CAR-NK therapy for advanced HER2-positive and triple-negative breast cancer

  This trial will test a dual-target CAR-NK cell therapy in adults with advanced HER2-positive or triple-negative breast cancer who have progressed on or cannot receive standard treatments.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07510802

• Dual-target CAR-NK therapy for advanced HER2-positive and triple-negative breast cancer

  This test gives a personalized dual-target CAR-NK cell infusion after short-course chemo to see if it is safe and can shrink tumors in adults with advanced HER2-positive or triple-negative breast cancer whose tumors express HER2, MUC1, or ROR1.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07486089

• ctDNA-guided sequential anti-HER2 therapy with CNS prophylaxis for HER2-positive metastatic breast cancer

  This trial will test whether using regular ctDNA blood tests to guide stepping up or down sequential anti-HER2 treatments, together with local therapies and measures to protect the brain and spinal cord, can produce long-lasting remission for people with HER2-positive stage IV breast cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07459673

• RO7771950 versus tucatinib with trastuzumab and capecitabine for HER2-positive locally advanced or metastatic breast cancer

  This test will see if RO7771950 combined with trastuzumab and capecitabine works better than tucatinib combined with the same drugs for people with HER2-positive locally advanced or metastatic breast cancer.

  Recruiting at 219 sites Phase 2/3 Hoffmann-La Roche · Huntsville, Alabama and 218 other locations · NCT07413939

• IBI354 with or without pertuzumab versus taxane plus trastuzumab and pertuzumab for HER2-positive metastatic breast cancer

  This trial tests whether IBI354, with or without pertuzumab, works better than standard taxane plus trastuzumab and pertuzumab as first-line treatment for adults with HER2-positive unresectable locally advanced or metastatic breast cancer.

  Recruiting Phase 3 Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Beijing, Beijing Municipality · NCT07377643

• Trastuzumab-rezetecan for HER2-positive and HER2-low breast cancer

  This project will test Trastuzumab-rezetecan in adults with HER2-positive or HER2-low breast cancer who are receiving it as part of routine care to see if it works and is safe.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07358182

• Trastuzumab deruxtecan for Russian patients with HER2-positive unresectable or metastatic breast cancer

  This study will see how well trastuzumab deruxtecan (T-DXd) works in Russian adults with unresectable or metastatic HER2-positive breast cancer who received at least one cycle.

  Recruiting Blokhin's Russian Cancer Research Center · Moscow · NCT07281001

• Nebivolol to protect the heart during trastuzumab treatment for HER2‑positive breast cancer

  This study will test whether taking nebivolol 5 mg can prevent drops in heart function in adults with newly diagnosed early or locally advanced HER2‑positive breast cancer who are starting trastuzumab.

  Recruiting Phase 2 Ain Shams University · Cairo · NCT07233499

• T-DXd with or without Neratinib for HER2-positive breast cancer with brain metastases

  This trial tests whether adding Neratinib to Trastuzumab Deruxtecan helps treat HER2-positive breast cancer that has spread to the brain.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07152782

• Neoadjuvant zanidatamab plus chemotherapy for HER2-positive early breast cancer

  This study will test if adding zanidatamab to chemotherapy given before surgery helps people with HER2-positive early-stage breast cancer.

  Recruiting at 53 sites Phase 2 Jazz Pharmaceuticals · Long Beach, California and 52 other locations · NCT07102381

• Treatment options after targeted therapy stops working in advanced breast cancer

  This study will see how well different treatments work for people with advanced breast cancer who have stopped responding to CDK4/6 inhibitors, PIK3CA inhibitors, or T-DXd.

  Recruiting Hunan Cancer Hospital · Changsha, Hunan · NCT07073755

• Surgery and focused radiation plus HER2-targeted therapy for oligometastatic HER2-positive breast cancer

  This will test whether adding surgery and precise radiation to standard HER2-targeted treatment helps people with oligometastatic HER2-positive breast cancer whose disease is controlled after initial therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07053085

• Neoadjuvant TQB2102 versus TCbHP for HER2-positive breast cancer

  This study will test whether TQB2102 given before surgery helps people with HER2-positive breast cancer as much as or better than the standard TCbHP treatment.

  Recruiting at 3 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Bengbu, Anhui and 76 other locations · NCT07043725

• Radiology-based prediction of HER2 level and T‑DXd benefit in metastatic breast cancer

  This study tests whether patterns in CT or FDG‑PET images can show HER2 level and help predict response to trastuzumab deruxtecan for people with metastatic breast cancer.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT07030569

• Oral capecitabine plus trastuzumab versus paclitaxel plus trastuzumab for small HER2‑positive, node‑negative breast cancers as adjuvant treatment.

  This trial tests whether giving oral capecitabine with trastuzumab instead of paclitaxel with trastuzumab can prevent recurrence in women with small (≤2 cm), HER2‑positive, node‑negative breast cancer.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT06992882

• Evaluating an intelligent management system for medication adherence in breast cancer treatment

  This study is testing a new patient management system to see if it helps women with HER2-positive breast cancer stick to their medication better than usual methods while they receive pyrotinib treatment.

  Recruiting Phase 2/3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06958627

• Vaccine targeting HER2 in locally advanced breast cancer

  This trial will test a vaccine that boosts the immune system to attack HER2-positive breast cancer in adults with locally advanced or high-risk disease.

  Recruiting Phase 1 Indiana University · Indianapolis, Indiana · NCT06949410

• Probiotics to prevent neratinib-related diarrhea in HER2-positive breast cancer patients

  This trial will test whether taking probiotics alongside standard preventive loperamide can reduce diarrhea in people with HER2-positive breast cancer who are starting neratinib compared with placebo.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06892093

• Neoadjuvant BL-M07D1 (with or without pertuzumab) versus taxane + trastuzumab + pertuzumab for HER2-positive breast cancer

  This trial will try whether giving the experimental antibody BL-M07D1, with or without pertuzumab, before surgery improves outcomes for people with HER2-positive breast cancer compared with the standard taxane plus trastuzumab and pertuzumab regimen.

  Recruiting Phase 2/3 Sichuan Baili Pharmaceutical Co., Ltd. · Bengbu, Anhui and 29 other locations · NCT06891833

• Combining chemotherapy with pyrotinib and trastuzumab for HER2-positive breast cancer

  This study is testing whether combining chemotherapy with two targeted drugs, pyrotinib and trastuzumab, can help people with HER2-positive breast cancer respond better to treatment before surgery.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou · NCT06832904

• BL-M07D1 versus T-DM1 after surgery for HER2‑positive breast cancer with residual invasive disease following neoadjuvant therapy

  This trial will test whether BL‑M07D1 works better than T‑DM1 as additional treatment after surgery for people with HER2‑positive breast cancer who still have invasive cancer following pre-surgery therapy.

  Recruiting at 2 sites Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Nanjing, Jiangsu and 1 other locations · NCT06830889

• Using pyrotinib and trastuzumab for maintenance therapy in HER2-positive breast cancer

  This study is testing if using the drugs pyrotinib and trastuzumab together can help people with advanced HER2-positive breast cancer stay healthier and prevent brain tumors after their initial treatment.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT06754059

• Combining chemotherapy and targeted therapy for early HER2 positive breast cancer

  This study is testing if combining chemotherapy with targeted therapy can help people with early HER2 positive breast cancer feel better while using less chemotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06722612

• Neoadjuvant therapy for low-risk HER2-positive breast cancer patients

  This study is testing a new treatment plan for people with low-risk HER2-positive breast cancer to see if combining certain chemotherapy drugs with targeted therapy can work just as well with less intense treatment.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06722599

• Targeted therapy for early HER2-positive breast cancer with no lymph node involvement

  This study is testing whether a new treatment approach that combines targeted therapy with less chemotherapy can help women with early HER2-positive breast cancer and no lymph node involvement feel better while reducing side effects.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06711068

• Combining taxane chemotherapy with targeted therapy for low-risk HER2 positive breast cancer

  This study is testing if combining a type of chemotherapy with a targeted therapy can safely treat patients with low-risk HER2 positive breast cancer and reduce the need for stronger treatments.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06711055

• Reducing chemotherapy for HER2 positive breast cancer patients

  This study is testing if using less chemotherapy can still be effective for patients with HER2 positive breast cancer while reducing side effects.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06700369

• Choosing adjuvant therapy for HER2 positive early breast cancer after initial treatment

  This study is testing whether a combination of trastuzumab and pertuzumab works better than T-DM1 for people with HER2 positive breast cancer who still have cancer after their initial treatment.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06693037

• Using Neratinib for Early HER2 Positive Breast Cancer Treatment

  This study is testing if taking neratinib after standard treatments can help people with early HER2 positive breast cancer live longer without the disease coming back.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06693024

• Tumor microenvironment changes after therapy in HER2‑positive breast cancer

  This project will compare tissue samples taken before and after standard neoadjuvant chemo plus trastuzumab to see if changes in the tumor microenvironment mark resistance in HER2‑positive breast cancer patients with residual disease.

  Recruiting IRCCS Ospedale San Raffaele · Milan, Lombardy · NCT06518382

• Reducing treatment for metastatic HER2-positive breast cancer with undetectable cancer levels in blood tests.

  This study is testing if patients with HER2-positive metastatic breast cancer can safely stop their treatment after two years of good results and negative blood tests showing no cancer.

  Recruiting Phase 2 Unicancer · Rennes · NCT06450314

• HER2DX-guided treatment for early-stage HER2-positive breast cancer

  This test tries to see if using the HER2DX diagnostic assay to guide personalized treatment can improve quality of life and outcomes for people with early-stage HER2-positive breast cancer.

  Recruiting at 29 sites Fundacio Clinic Barcelona · Graz and 28 other locations · NCT06446882

• Optimizing Biomarkers for Neoadjuvant Therapy in HER2-positive Breast Cancer

  This study is testing if a special test on breast cancer samples can help doctors choose the best chemotherapy for adults with early-stage HER2-positive breast cancer.

  Recruiting Phase 2 University of Illinois Chicago · Chicago, Illinois · NCT06441890

• Sequential therapy for HER2-positive metastatic breast cancer

  This study is testing whether giving a specific order of HER2-targeted drugs can help people with HER2-positive metastatic breast cancer feel better and live longer.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06439693

• Vaccine therapy for metastatic solid tumors

  This study is testing a new vaccine therapy to see if it can safely help people with certain types of advanced breast and stomach cancers fight their tumors better.

  Recruiting Phase 1 Indiana University · Indianpolis, Indiana · NCT06414733

• Identifying risk factors for brain recurrence in HER2-positive breast cancer patients

  This study is trying to find out what factors might lead to brain cancer returning in patients with HER2-positive breast cancer to help improve their treatment and care.

  Recruiting Center Eugene Marquis · Rennes · NCT06358625

• Testing anti-HER2 treatment before and after surgery for Nigerian women with HER2+ breast cancer

  This study will test whether giving anti-HER2 drugs with chemotherapy before and after surgery helps Nigerian women with HER2-positive breast cancer.

  Recruiting at 4 sites Phase 2 University of Chicago · Ikeja, Lagos and 3 other locations · NCT06348134

• Understanding how trastuzumab deruxtecan works in HER2 positive breast cancer

  This study is trying to understand why some people with HER2 positive breast cancer don’t respond to the treatment trastuzumab deruxtecan, to help improve future treatment options.

  Recruiting Samsung Medical Center · Seoul · NCT06330012

• Using MRI to detect early breast cancer metastases

  This study is testing if a special type of MRI can help find early signs of breast cancer returning in high-risk patients to see if it can improve their chances of living longer.

  Recruiting European Institute of Oncology · Milan · NCT06328465

• Comparing DP303c and trastuzumab emtansine for advanced HER2-positive breast cancer

  This study is testing a new injection called DP303c to see if it works better than trastuzumab emtansine for people with advanced HER2-positive breast cancer.

  Recruiting Phase 3 CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Shanghai, Shanghai Municipality · NCT06313086

• Non-surgical treatment for breast cancer after chemotherapy

  This study tests if using radiotherapy alone is a safe and effective option for breast cancer patients who have responded well to chemotherapy, instead of undergoing surgery.

  Recruiting European Institute of Oncology · Candiolo, Turin and 1 other locations · NCT06281210

• Combining Darsilide with Trastuzumab and Patuzumab for Breast Cancer Treatment

  This study is testing if a new treatment combining Darsilide with two other drugs can help women with early or locally advanced HER2-positive breast cancer before they have surgery.

  Recruiting Phase 2 Henan Cancer Hospital · Henan, Henan · NCT06276868

• Evaluating IAM1363 for HER2-related cancers

  This study is testing a new treatment called IAM1363 to see if it can help people with advanced cancers that have changes in the HER2 gene.

  Recruiting at 53 sites Phase 1 Iambic Therapeutics, Inc · La Jolla, California and 52 other locations · NCT06253871

• Using advanced mammography techniques to assess breast cancer treatment response

  This study is testing two new mammography techniques to see if they can better predict how well chemotherapy is working for people with locally advanced breast cancer.

  Recruiting Early Phase 1 Stony Brook University · Stony Brook, New York · NCT06220214

• Assessing Trastuzumab Deruxtecan in Chinese Patients with HER2-positive and HER2-low Breast Cancer

  This study is testing how well Trastuzumab Deruxtecan works for Chinese patients with advanced HER2-positive or HER2-low breast cancer who have already tried other treatments.

  Recruiting at 46 sites Daiichi Sankyo · Beijing and 53 other locations · NCT06210776

• Effects of fasting and exercise on fatigue in women with advanced breast cancer

  This study is testing whether fasting, exercise, a mix of both, or health education can help reduce fatigue in postmenopausal women with advanced breast cancer who are starting hormone therapy.

  Recruiting at 2 sites University of Miami · Phoenix, Arizona and 2 other locations · NCT06123988

• Investigating ctDNA in Breast Cancer Treatment

  This study is testing if blood samples can help predict how well neoadjuvant chemotherapy works for women with stage II-III HER2-positive and triple-negative breast cancer.

  Recruiting at 3 sites Gene Solutions · Jakarta and 2 other locations · NCT06087120

• Combining Pyrotinib and Capecitabine for HER2 Positive Early-stage Breast Cancer Treatment

  This study is testing if combining two drugs, Pyrotinib and Capecitabine, can help women with early-stage HER2 positive breast cancer after surgery feel better compared to other treatments their doctors choose.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06035016

• Tucatinib combined with radiation for HER2-positive breast cancer with leptomeningeal disease

  This study is testing if combining radiation with a new treatment for HER2-positive breast cancer can help patients with brain involvement live longer and feel better.

  Recruiting at 2 sites Phase 2 Sunnybrook Health Sciences Centre · Ottawa, Ontario and 1 other locations · NCT06016387

• Treatment for HER2-positive breast cancer with limited metastases

  This study tests if a new treatment can help people with HER2-positive breast cancer that has spread to a few other places in the body and aims to improve their chances of recovery.

  Recruiting Phase 2 The Netherlands Cancer Institute · Amsterdam · NCT05982678

• Combination treatment for metastatic HER2-positive breast cancer

  This study is testing a new combination of medications for people with HER2-positive metastatic breast cancer who haven't responded to previous treatments, to see if it can help them feel better and manage their disease.

  Recruiting at 9 sites Phase 2 Institut Curie · Clermont-Ferrand, Clermont Ferrand and 12 other locations · NCT05955170

• Comparing two treatments for HER2-positive breast cancer before surgery

  This study is testing a new combination of drugs to see if it works better than standard treatment for people with HER2-positive breast cancer before surgery.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT05918328

• Platform program for evaluating treatments in metastatic HER2-positive breast cancer

  This study is testing different new treatments for people with advanced HER2-positive breast cancer to see which ones work best before moving them to larger trials.

  Recruiting at 5 sites Phase 1/2 QuantumLeap Healthcare Collaborative · Birmingham, Alabama and 9 other locations · NCT05868226

• Using Pyrotinib to Reduce Recurrence Risk in Early Stage HER2-positive Breast Cancer

  This study is testing if the drug pyrotinib can help reduce the chances of breast cancer coming back in women with early stage HER2-positive breast cancer who haven't fully responded to previous treatments.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT05834764

• Testing a new drug combination for HER2-positive inflammatory breast cancer

  This study is testing a new combination of two drugs to see if they can safely and effectively treat people with stage III HER2-positive inflammatory breast cancer who haven't had treatment before.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT05795101

• Treatment for hormone receptor positive HER2 positive breast cancer after neoadjuvant therapy

  This study is testing if combining two drugs, trastuzumab and nelatinib, can help people with hormone receptor positive HER2 positive breast cancer who still have cancer after initial treatment feel better compared to the usual combination of trastuzumab and pertuzumab.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou · NCT05760612

• Neoadjuvant treatment for HER2-positive breast cancer using SHR-A1811 and pyrotinib

  This study is testing a new combination of two drugs, SHR-A1811 and pyrotinib, to see if they can help people with Stage II-III HER2-positive breast cancer before surgery.

  Recruiting Phase 2 Shengjing Hospital · Shenyang, Liaoning · NCT05635487

• Precision neoadjuvant therapy for operable breast cancer

  This study is testing if a personalized treatment approach using new drugs for operable breast cancer can work better than standard chemotherapy alone.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05582499

• Assessing minimal residual disease in HER2-positive early breast cancer patients in Asia

  This study is trying to see if checking for tiny amounts of cancer DNA in the blood can help predict if HER2-positive early breast cancer patients in Asia are at risk of their cancer coming back after treatment.

  Recruiting National Cancer Center, Japan · Chuo-ku, Tokyo · NCT05433753

• Using Kadcyla and Neratinib to Treat Early HER2-positive Breast Cancer with Residual Disease

  This study is testing if adding a pill called neratinib to the standard treatment can help people with early HER2-positive breast cancer who still have some cancer cells left after their initial therapy.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT05388149

• HER2-targeted vaccine combined with standard chemotherapy for breast cancer

  This study is testing if adding a new vaccine to standard chemotherapy can help people with HER2-positive breast cancer have better treatment results.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT05325632

• Neoadjuvant therapy with or without Inavolisib for early HER2-positive breast cancer

  This study is testing if adding a new drug called Inavolisib to standard treatment can help women with early HER2-positive breast cancer respond better before surgery.

  Recruiting at 53 sites Phase 2 GBG Forschungs GmbH · Essen, North Rhine-Westphalia and 61 other locations · NCT05306041

• Screening brain MRIs for patients with stage IV breast cancer

  This study tests if regular brain MRI scans can help find hidden issues in the brains of patients with stage IV breast cancer who don’t have any symptoms yet.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Clearwater, Florida and 1 other locations · NCT05115474

• Understanding how tumor shrinkage predicts cancer response in early breast cancer patients

  This study tests if measuring how much breast tumors shrink during chemotherapy can help predict how well the treatment will work for women with early-stage breast cancer.

  Recruiting at 2 sites Phase 2 Baylor Breast Care Center · Houston, Texas and 1 other locations · NCT05020860

• Treatment adjustment for HER2 positive breast cancer after initial therapy

  This study is testing if adjusting treatment for early HER2 positive breast cancer based on blood tests can help patients do better after their initial therapy.

  Recruiting Phase 2 AC Camargo Cancer Center · São Paulo · NCT04993014

• Using nanoparticles to enhance radiation treatment for brain metastases

  This study is testing if adding special nanoparticles to radiation therapy can help people with brain metastases get better results than radiation alone.

  Recruiting at 2 sites Phase 2 Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT04899908

• Comparing two treatments for early-stage HER2-positive breast cancer after surgery

  This study is testing whether a new treatment combining T-DM1 and trastuzumab can help people with early-stage HER2-positive breast cancer feel better and live longer after surgery compared to a standard treatment.

  Recruiting at 46 sites Phase 2 Dana-Farber Cancer Institute · San Francisco, California and 52 other locations · NCT04893109

• Pre-operative treatment for HER2-positive, ER-positive breast cancer

  This study is testing if a new combination of treatments can help women with HER2-positive, ER-positive breast cancer before they have surgery.

  Recruiting at 4 sites Phase 2 Hoosier Cancer Research Network · Chicago, Illinois and 3 other locations · NCT04886531

• Identifying genetic factors affecting treatment response in HER2-positive breast cancer

  This study is trying to find out how genetic differences affect how well people with HER2-positive breast cancer respond to treatment and if they experience side effects.

  Recruiting Centre Paul Strauss · Strasbourg · NCT04638725

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• Combining trastuzumab with pyrrolidine and chemotherapy for HER2-positive breast cancer

  This study is testing a new treatment combining trastuzumab, pyrrolidine, and chemotherapy for people with advanced HER2-positive breast cancer to see if it helps them respond better before surgery.

  Recruiting Phase 2 Peking University · Beijing, Beijing Municipality · NCT04481932

• Monitoring HER2-positive breast cancer treatment with advanced imaging techniques

  This study is testing a new imaging agent to see if it can help track how well HER2-positive breast cancer patients are responding to their treatment with trastuzumab during chemotherapy.

  Recruiting Phase 1 University of Alabama at Birmingham · Birmingham, Alabama · NCT04332588

• Evaluating a new treatment approach for operable HER2-positive breast cancer

  This study is testing a new combination of medications and chemotherapy before surgery to see if it helps people with HER2-positive breast cancer achieve better treatment results.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT04281641

• Personalized treatment for breast cancer using new drug agents

  This study is testing new drug combinations with standard chemotherapy to see which treatments work best for different types of breast cancer based on the specific characteristics of each patient's tumor.

  Recruiting at 32 sites Phase 2 QuantumLeap Healthcare Collaborative · Birmingham, Alabama and 41 other locations · NCT01042379

NIH-funded research (11)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Enhancing HER2-targeted therapy for resistant breast cancer

  This grant explores new ways to overcome resistance to HER2-targeted therapy in people with HER2-positive breast cancer.

  NIH research Lsu Health Sciences Center · New Orleans, United States · NIH-11457632

• Prolactin signaling and brain metastasis in HER2-positive breast cancer

  Researchers are studying how prolactin signals help HER2-positive breast cancer cells grow in the brain, with the goal of finding new ideas to prevent brain metastases.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11434654

• XoLacta adjuvant therapy to reduce radiation side effects during HER2-positive breast cancer treatment

  A new milk-derived therapy called XoLacta aims to lessen radiation-related side effects for people undergoing treatment for HER2-positive breast cancer.

  NIH research Tiny Cargo Company, the · Roanoke, United States · NIH-11413717

• Ig repertoire in tumor-infiltrating B cells in metastatic HER2-positive breast cancer (mouse model)

  Scientists will study how antibodies from immune cells inside HER2-positive breast tumors behave in a mouse model to understand potential new ways to fight the cancer.

  NIH research Texas Southern University · Houston, United States · NIH-11413688

• Autophagy and vesicle trafficking linked to HER2+ breast cancer progression

  A cancer research project aims to understand how cell recycling processes and vesicle movement affect HER2-positive breast cancer, with potential implications for metastasis and resistance to therapy.

  NIH research University of Cincinnati · Cincinnati, United States · NIH-11320779

• XoLacta to reduce radiation side effects in HER2-positive breast cancer

  XoLacta, a milk-derived therapy given during radiation, aims to help people with HER2-positive breast cancer heal better and have fewer side effects.

  NIH research Tiny Cargo Company, the · Roanoke, United States · NIH-11254142

• Why some HER2-positive breast cancers survive targeted therapy

  This project looks for the specific cancer cells that survive HER2-targeted drugs in people with HER2-positive breast cancer to find ways to stop drug resistance.

  NIH research New York University School of Medicine · New York, United States · NIH-11251236

• Understanding how cell processes affect HER2-positive breast cancer

  This study is looking at how certain processes in cells work together in HER2-positive breast cancer, which affects about 1 in 4 breast cancer patients, to find new ways to stop the cancer from spreading and becoming resistant to treatment, with the hope of improving care for those living with this type of cancer.

  NIH research University of Cincinnati · Cincinnati, United States · NIH-11098576

• Understanding how some HER2 positive breast cancer cells survive treatment

  This study is looking at why some HER2 positive breast cancer cells can survive treatment and how they go into a resting state, which might help us find better ways to stop these cells from resisting therapy and improve outcomes for patients like you.

  NIH research New York University School of Medicine · New York, United States · NIH-11002660

• Finding ways to overcome drug resistance in HER2-positive breast cancer

  This study is looking at a new treatment called PEPDG278D that might help people with HER2-positive breast cancer who haven't had success with other therapies, by targeting and breaking down the cancer's growth signals.

  NIH research Virginia Commonwealth University · Richmond, United States · NIH-10911307

• Understanding resistance in HER2-positive breast cancer treatments

  This study is looking into why some patients with HER2-positive breast cancer don't respond well to certain treatments, focusing on different forms of the HER2 protein that might be causing issues, with the goal of finding better ways to help those who have had their cancer come back.

  NIH research University of California Berkeley · Berkeley, United States · NIH-10778574

Related topics

Quick answers

How many HER2-positive Breast Cancer clinical trials are recruiting right now?

83, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 38 countries. The most sites are in China (40 trials), United States (23 trials), Italy (10 trials), France (8 trials), Spain (6 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 33, Phase 3: 8, Phase 1/2: 5, Phase 1: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →